Join our community of traders FOR FREE!

  • Learn
  • Improve yourself
  • Get Rewards
Learn More

Eli Lilly and Companys quarterly revenue and profit, reported on Tuesday, topped Wall Street estimates, supported by higher sales of diabetes drugs Trulicity and Basaglar.

Eli Lilly shares closed lower for the fourth time in the past twelve trading sessions in New York on Tuesday. The stock inched down 0.03% ($0.03) to $108.69, after touching an intraday low at $107.00, or a price level not seen since July 23rd ($106.06).

Shares of Eli Lilly and Company have retreated 6.08% so far in 2019 compared with a 20.20% gain for the benchmark index, S&P 500 (SPX).

In 2018, Eli Lilly’s stock went up 37.01%, thus, it outperformed the S&P 500, which registered a 6.24% loss.

Eli Lilly’s second-quarter revenue, reported at $5.64 billion, exceeded market consensus of $5.59 billion.

The company’s top-selling diabetes drug, Trulicity, generated $1.03 billion in revenue during the second quarter and also outstripped the median analyst estimate of $1.02 billion.

Net income attributable to shareholders was reported at $1.33 billion ($1.44 per share) during the quarter ended on June 30th, after the company posted a net loss of $259.9 million ($0.25 per share) in the same period a year earlier due to acquisition-related charges of $1.62 billion.

Meanwhile, earnings per share, which exclude special items, were reported at $1.50 during the second quarter, thus, exceeding the median analyst estimate of $1.45 per share.

Eli Lilly also revised up its full-year 2019 adjusted earnings forecast to a range of $5.67-$5.77 per share from a previously expected range of $5.60-$5.70 per share.

Analyst stock price forecast and recommendation

According to CNN Money, the 11 analysts, offering 12-month forecasts regarding Eli Lilly and Co’s stock price, have a median target of $131.00, with a high estimate of $145.00 and a low estimate of $93.00. The median estimate represents a 20.53% upside compared to the closing price of $108.69 on July 30th.

The same media also reported that at least 8 out of 14 surveyed investment analysts had rated Eli Lilly and Co’s stock as “Hold”, while 6 – as “Buy”.

TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover Forex, Price Action and Social Trading.

Related News

  • Forex Market: EUR/USD daily trading forecastForex Market: EUR/USD daily trading forecast Yesterday’s trade saw EUR/USD within the range of 1.0869-1.0966. The pair closed at 1.0934, dipping 0.03% on a daily basis. On July 21st the cross climbed as high as 1.0970, which has been the highest level since July 15th, when a high of […]
  • Forex Market: EUR/CHF daily trading outlookForex Market: EUR/CHF daily trading outlook Yesterday’s trade saw EUR/CHF within the range of 1.2068-1.2036. The pair closed at 1.2041, down 0.14% on a daily basis.At 7:28 GMT today EUR/CHF was up 0.01% for the day to trade at 1.2045. The pair touched held in a daily range of […]
  • Forex Market: USD/CAD daily trading outlookForex Market: USD/CAD daily trading outlook Yesterday’s trade saw USD/CAD within the range of 1.2992-1.3102. The pair closed at 1.3094, rising 0.71% on a daily basis. It has been the 29th gain in the past 55 trading days and also a second consecutive one. The daily high has been the […]
  • UK stocks fluctuate as stimulus program continuesUK stocks fluctuate as stimulus program continues The UK main index FTSE 100 climbed 36.4 points or 0.5 percent to 6,840.27 adding to the 16 percent raise since the beginning of the year. UK stocks went up on Fed Chairman Ben Bernankes testimony that economy is not quite ready for a […]
  • Netflix stock surge 10% on better than expected earnings amid highly successful original contentNetflix stock surge 10% on better than expected earnings amid highly successful original content Netflix shares surged about 10% in after-market trading yesterday as streaming service reported it attracted more than 40 million global subscribers and tripled profits in the third quarter, beating analysts’ estimates.The company behind […]
  • AUD/USD falls as US retail sales report supports the view of further tapering by FedAUD/USD falls as US retail sales report supports the view of further tapering by Fed Australian dollar traded lower against its US counterpart on Wednesday, after yesterdays report on retail sales in the United States supported expectations that the Federal Reserve Bank may continue to pare back its monthly monetary stimulus […]